Dr. Pablo Perez-Pinera has developed a method to divide prime editing tools into smaller components that are small enough to be delivered in adeno-associated viruses, an FDA-approved vehicle for therapeutic use. Prime editors have recently shown great promise as gene editing tools with greater specificity and fewer off-target effects than existing CRISPR-Cas based methods. This technology has potential as a research tool as well as a therapeutic strategy.